Steven Cohen's ALNY Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 6.2K shares of Alnylam Pharmaceuticals, Inc. (ALNY) worth $2.83 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in ALNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2018, adding 819.2K shares. Largest reduction occurred in Q2 2019, reducing 486.4K shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Alnylam Pharmaceuticals (ALNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Alnylam Pharmaceuticals (ALNY) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +12,100 | New Buy | 12,100 | $78.10 |
| Q4 2014 | -12,100 | Sold Out | 12,100 | $0.00 |
| Q2 2017 | +50,000 | New Buy | 50,000 | $79.76 |
| Q3 2017 | +35,000 | Add 70.00% | 85,000 | $117.49 |
| Q4 2017 | +3,886 | Add 4.57% | 88,886 | $127.05 |
| Q1 2018 | +819,160 | Add 921.58% | 908,046 | $119.10 |
| Q2 2018 | +448,362 | Add 49.38% | 1.36 M | $98.49 |
| Q3 2018 | -471,096 | Reduce 34.73% | 885,312 | $87.52 |
| Q4 2018 | -885,312 | Sold Out | 885,312 | $0.00 |
| Q2 2019 | +398,928 | New Buy | 398,928 | $72.56 |
| Q3 2019 | -398,928 | Sold Out | 398,928 | $0.00 |
| Q4 2020 | +481,900 | New Buy | 481,900 | $129.97 |
| Q1 2021 | -41,963 | Reduce 8.71% | 439,937 | $141.19 |
| Q2 2021 | -320,248 | Reduce 72.79% | 119,689 | $169.52 |
| Q3 2021 | -20,177 | Reduce 16.86% | 99,512 | $188.81 |
| Q4 2021 | -99,512 | Sold Out | 99,512 | $0.00 |
| Q2 2022 | +333,200 | New Buy | 333,200 | $145.85 |
| Q3 2022 | -318,630 | Reduce 95.63% | 14,570 | $200.14 |
| Q4 2022 | -14,570 | Sold Out | 14,570 | $0.00 |
| Q4 2023 | +85,990 | New Buy | 85,990 | $191.41 |
| Q1 2024 | +120,265 | Add 139.86% | 206,255 | $149.45 |
| Q2 2024 | -206,255 | Sold Out | 206,255 | $0.00 |
| Q1 2025 | +300,635 | New Buy | 300,635 | $270.02 |
| Q2 2025 | -99,239 | Reduce 33.01% | 201,396 | $326.09 |
| Q3 2025 | -195,199 | Reduce 96.92% | 6,197 | $456.00 |
Steven Cohen's Alnylam Pharmaceuticals Investment FAQs
Steven Cohen first purchased Alnylam Pharmaceuticals, Inc. (ALNY) in Q3 2014, acquiring 12,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Alnylam Pharmaceuticals, Inc. (ALNY) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to Alnylam Pharmaceuticals, Inc. (ALNY) was in Q1 2018, adding 908,046 shares worth $108.15 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 6,197 shares of Alnylam Pharmaceuticals, Inc. (ALNY), valued at approximately $2.83 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Alnylam Pharmaceuticals, Inc. (ALNY) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in Alnylam Pharmaceuticals, Inc. (ALNY) was 1,356,408 shares, as reported at the end of Q2 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.